Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1043033 | 0.80 | CA2 (0.40) | CA2GABRA1GABRB2ALDH1A1TSHR | |
| SCHEMBL1041734 | 0.80 | CA2 (0.40) | CA2GABRA1GABRB2ALDH1A1TSHR | |
| SCHEMBL1039758 | 0.78 | CES2 (0.36) | — | |
| SCHEMBL1041027 | 0.72 | ACHE (0.48) | CA2ALDH1A1TSHR | |
| SCHEMBL6763814 | 0.72 | CA2 (0.48) | CA2GABRA1GABRB2ALDH1A1TSHR | |
| SCHEMBL5699639 | 0.71 | CA2 (0.52) | CA2GABRA1GABRB2ALDH1A1TSHR | |
| SCHEMBL179259 | 0.71 | ALDH1A1 (0.50) | CA2GABRA1GABRB2ALDH1A1TSHR | |
| SCHEMBL1041308 | 0.71 | GABRA1 (0.31) | GABRA1GABRB2 | |
| SCHEMBL1041648 | 0.71 | SMN1; SMN2 (0.42) | CA2ALDH1A1 | |
| SCHEMBL8254661 | 0.70 | CA2 (0.46) | CA2GABRA1GABRB2ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915455-B2 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-03-29 | — | — | US | disclosed |
| EP-2272852-A1 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | Sumitomo Chemical Company, Limited (JP) | 2011-01-12 | — | — | EP | disclosed |
| US-20090143620-A1 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED | 2009-06-04 | — | — | US | disclosed |
| US-7482414-B2 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-01-27 | — | — | US | disclosed |
| US-20070135600-A1 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-06-14 | — | — | US | disclosed |
| EP-1683802-A1 | TRANSITION METAL COMPLEX LIGAND AND OLEFIN POLYMERIZATION CATALYST CONTAINING TRANSITION METAL COMPLEX | Sumitomo Chemical Company, Limited (JP) | 2006-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135600-A1 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | AP1M1, OR10J3, AP2M1 | CA2 1200/4885GABRA1 4418/4885GABRB2 4604/4885 |
| US-20090143620-A1 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | AP1M1, OR10J3, AP2M1 | CA2 1200/4885GABRA1 4418/4885GABRB2 4604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.